RU2452729C2 - Biphenyl derivatives and application thereof in treating hepatitis c - Google Patents

Biphenyl derivatives and application thereof in treating hepatitis c Download PDF

Info

Publication number
RU2452729C2
RU2452729C2 RU2008114210/04A RU2008114210A RU2452729C2 RU 2452729 C2 RU2452729 C2 RU 2452729C2 RU 2008114210/04 A RU2008114210/04 A RU 2008114210/04A RU 2008114210 A RU2008114210 A RU 2008114210A RU 2452729 C2 RU2452729 C2 RU 2452729C2
Authority
RU
Russia
Prior art keywords
application
treating hepatitis
biphenyl derivatives
compound
treating
Prior art date
Application number
RU2008114210/04A
Other languages
Russian (ru)
Other versions
RU2008114210A (en
Inventor
Кристофер Джеймс ВИЛЛХАУС (GB)
Кристофер Джеймс ВИЛЛХАУС
Александер Джеймс Флойд ТОМАС (GB)
Александер Джеймс Флойд Томас
Дейвид Джон БАШНЕЛЛ (GB)
Дейвид Джон БАШНЕЛЛ
Джеймс ЛАМЛИ (GB)
Джеймс ЛАМЛИ
Джеймс Айан СОЛТЕР (GB)
Джеймс Айан СОЛТЕР
Малколм Клайв КАРТЕР (GB)
Малколм Клайв КАРТЕР
Нил МАТЬЮС (GB)
Нил МАТЬЮС
Кристофер Джон ПИЛКИНГТОН (GB)
Кристофер Джон Пилкингтон
Ричард Мартин ЭЙНДЖЕЛ (GB)
Ричард Мартин ЭЙНДЖЕЛ
Original Assignee
Арроу Терапьютикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0518971.7A external-priority patent/GB0518971D0/en
Priority claimed from GB0610663A external-priority patent/GB0610663D0/en
Application filed by Арроу Терапьютикс Лимитед filed Critical Арроу Терапьютикс Лимитед
Publication of RU2008114210A publication Critical patent/RU2008114210A/en
Application granted granted Critical
Publication of RU2452729C2 publication Critical patent/RU2452729C2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FIELD: medicine.
SUBSTANCE: invention refers to a compound which represents a biphenyl derivative of formula
Figure 00000167
. What is also described is a pharmaceutical composition for treating or relieving HCV on the basis of said compound.
EFFECT: higher efficacy of the composition.
3 cl, 265 ex

Description

Текст описания приведен в факсимильном виде.

Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131
Figure 00000132
Figure 00000133
Figure 00000134
Figure 00000135
Figure 00000136
Figure 00000137
Figure 00000138
Figure 00000139
Figure 00000140
Figure 00000141
Figure 00000142
Figure 00000143
Figure 00000144
Figure 00000145
Figure 00000146
Figure 00000147
Figure 00000148
Figure 00000149
Figure 00000150
Figure 00000151
Figure 00000152
Figure 00000153
Figure 00000154
Figure 00000155
Figure 00000156
Figure 00000157
Figure 00000158
Figure 00000159
Figure 00000160
Figure 00000161
Figure 00000162
Figure 00000163
Figure 00000164
Figure 00000165
The text of the description is given in facsimile form.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131
Figure 00000132
Figure 00000133
Figure 00000134
Figure 00000135
Figure 00000136
Figure 00000137
Figure 00000138
Figure 00000139
Figure 00000140
Figure 00000141
Figure 00000142
Figure 00000143
Figure 00000144
Figure 00000145
Figure 00000146
Figure 00000147
Figure 00000148
Figure 00000149
Figure 00000150
Figure 00000151
Figure 00000152
Figure 00000153
Figure 00000154
Figure 00000155
Figure 00000156
Figure 00000157
Figure 00000158
Figure 00000159
Figure 00000160
Figure 00000161
Figure 00000162
Figure 00000163
Figure 00000164
Figure 00000165

Claims (3)

1. Соединение
Figure 00000166
1. Connection
Figure 00000166
 2. Фармацевтическая композиция, предназначенная для лечения или облегчения HCV, включающая соединение по п.1 и фармацевтически приемлемый разбавитель или носитель.2. A pharmaceutical composition for treating or alleviating HCV, comprising the compound of claim 1 and a pharmaceutically acceptable diluent or carrier. 3. Применение соединения по п.1 для изготовления лекарственного средства, предназначенного для применения для лечения или облегчения HCV. 3. The use of a compound according to claim 1 for the manufacture of a medicament for use in the treatment or amelioration of HCV.
RU2008114210/04A 2005-09-16 2006-09-18 Biphenyl derivatives and application thereof in treating hepatitis c RU2452729C2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0518971.7A GB0518971D0 (en) 2005-09-16 2005-09-16 Chemical compounds
GB0518971.7 2005-09-16
GB0610663A GB0610663D0 (en) 2006-05-30 2006-05-30 Chemical compounds
GB0610664.5 2006-05-30
GB0610663.7 2006-05-30

Publications (2)

Publication Number Publication Date
RU2008114210A RU2008114210A (en) 2009-10-27
RU2452729C2 true RU2452729C2 (en) 2012-06-10

Family

ID=41352403

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008114210/04A RU2452729C2 (en) 2005-09-16 2006-09-18 Biphenyl derivatives and application thereof in treating hepatitis c

Country Status (1)

Country Link
RU (1) RU2452729C2 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2194035C2 (en) * 1996-03-08 2002-12-10 Новартис Аг Triaryl compounds, method of their synthesis, pharmaceutical composition based on thereof, method of treatment and intermediates substances
EP1295867A1 (en) * 2000-06-28 2003-03-26 Takeda Chemical Industries, Ltd. Biphenyl compound
WO2003032972A1 (en) * 2001-10-17 2003-04-24 Glaxo Group Limited 5’-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
WO2003032970A1 (en) * 2001-10-17 2003-04-24 Glaxo Group Limited 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
WO2003032980A1 (en) * 2001-10-17 2003-04-24 Glaxo Group Limited 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
WO2004089876A1 (en) * 2003-04-09 2004-10-21 Smithkline Beecham Corporation Biphenylcarboxylic amide derivatives as p38 kinease inhibitors
WO2004089874A1 (en) * 2003-04-09 2004-10-21 Smithkline Beecham Corporation Biphenyl carboxylic amide p38 kinase inhibitors
US20050020590A1 (en) * 2003-07-25 2005-01-27 Hengyuan Lang P-38 kinase inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2194035C2 (en) * 1996-03-08 2002-12-10 Новартис Аг Triaryl compounds, method of their synthesis, pharmaceutical composition based on thereof, method of treatment and intermediates substances
EP1295867A1 (en) * 2000-06-28 2003-03-26 Takeda Chemical Industries, Ltd. Biphenyl compound
WO2003032972A1 (en) * 2001-10-17 2003-04-24 Glaxo Group Limited 5’-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
WO2003032970A1 (en) * 2001-10-17 2003-04-24 Glaxo Group Limited 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
WO2003032980A1 (en) * 2001-10-17 2003-04-24 Glaxo Group Limited 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
WO2004089876A1 (en) * 2003-04-09 2004-10-21 Smithkline Beecham Corporation Biphenylcarboxylic amide derivatives as p38 kinease inhibitors
WO2004089874A1 (en) * 2003-04-09 2004-10-21 Smithkline Beecham Corporation Biphenyl carboxylic amide p38 kinase inhibitors
US20050020590A1 (en) * 2003-07-25 2005-01-27 Hengyuan Lang P-38 kinase inhibitors

Also Published As

Publication number Publication date
RU2008114210A (en) 2009-10-27

Similar Documents

Publication Publication Date Title
RU2384580C2 (en) Phosphatidylinositol-3-kinase inhibitors
RU2401658C2 (en) Heterocyclic aspartylprotease inhibitors
RU2470016C2 (en) Bipirazole derivative
CY1111050T1 (en) PHOSPHONES, MONO-PHOSPHONAMIDES, BISPHOSPHONAMIDES FOR THE TREATMENT OF VIRUS DISEASES
RU2498988C2 (en) Protein tyrosine kinase activity inhibitors
EA200601467A1 (en) MACROCYCLIC COMPOUNDS AS VIRAL REPLICATION INHIBITORS
RU2325389C2 (en) Composition and derivatives of substituted azaindoloxoacetapiperazine characterized by antiviral activity
EA201100795A1 (en) PHARMACEUTICAL COMPOSITION OF EFFICIENT HSG INHIBITOR FOR ORAL ADMINISTRATION
EA201200096A1 (en) PHARMACEUTICAL COMPOSITION OF THE HYPATITIS VIRUS PROTEASE INHIBITOR INHIBITOR
IL207468A (en) Hcv inhibitors and use thereof for the preparation of medicaments for treatment of hcv infections
CL2007003250A1 (en) COMPOUNDS DERIVED FROM ISOQUINOLINE, INHIBITORS OF THE HEPATITIS C VIRUS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF AN HCV INFECTION.
RU2008139905A (en) PHARMACEUTICAL COMPOSITION FOR EXTERNAL USE
WO2007076034A3 (en) Anti-viral compounds
WO2007047146A3 (en) Inhibitors of viral replication
RS20110578A2 (en) Macrocyclic carboxylic acids and acyl sulfonamides as inhibitors of hcv replication
EA200800178A1 (en) HEPATITIS C VIRUS INHIBITORS (HCV)
EP2103623A3 (en) Novel macrocyclic inhibitors of Hepatitis C virus replication
EA200901241A1 (en) CONNECTIONS FOR THE TREATMENT OF HEPATITIS C
CL2004001161A1 (en) COMPOUNDS DESCRIBES COMPOUNDS DERIVED FROM QUINOLINA; PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT AN ILLNESS CAUSED BY THE HEPATITIS C VIRUS.
MY159958A (en) 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
SV2005001920A (en) "NUCLEOSID COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS"
JP2011528713A5 (en)
AR043929A1 (en) CRYSTAL PHASES OF AN HCV INHIBITOR
JP2005537234A5 (en)
EA201000277A1 (en) CONNECTIONS FOR THE TREATMENT OF HEPATITIS C

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120919